Cell death by necrosis, unlike other forms of programmed cell death, is immunogenic and associated with many disease pathologies. Recent work indicates that death cytokines in the TNF family can induce a ''programmed'' form of necrosis through the kinases RIP1 and RIP3 when caspases are inhibited. Genetic experiments have recently determined that RIP1-and RIP3-driven programmed necrosis is crucial during embryonic development, certain viral infections, tissue injury/inflammation, and clonal expansion of antigen-specific lymphocytes (reviewed in Oberst and Green, 2011) . Beyond RIP1 and RIP3, however, our understanding of the molecular regulation of programmed necrosis remains limited. In this issue of Cell, Wang and colleagues provide convincing evidence that mixed lineage kinase domain-like (MLKL) and phosphoglycerate mutase 5 (PGAM5) are integral parts of the necrosis signaling machinery downstream of RIP1 and RIP3 activation and are RIP3 substrates (Sun et al., 2012; Wang et al., 2012) .
RIP1 is a critical adaptor for NF-kB activation through multiple immune signaling receptors. Paradoxically, it also mediates cell death by apoptosis and programmed necrosis. Necrosis signaling by RIP1 requires interaction with RIP3. Unlike RIP1, RIP3 does not participate in NF-kB or apoptosis signaling (Moquin and Chan, 2010) . Because the kinase functions of RIP1 and RIP3 are essential for programmed necrosis, identifying their substrates holds the key in understanding the regulation of this poorly defined process. Pharmacological inhibition of RIP1 abolished RIP3 recruitment and activation of the necrosis-inducing complex, suggesting that RIP1 is likely the upstream activating kinase for RIP3 (Cho et al., 2009; He et al., 2009) . By contrast, the substrates of RIP3 have remained elusive. Although mitochondrial enzymes were previously implicated as substrates for RIP3, their roles in programmed necrosis have yet to be independently validated (Zhang et al., 2009) .
To identify putative RIP3 substrates, Sun et al. use a chemical library screening approach to identify a small molecule named necrosulfonamide (NSA) that blocks programmed necrosis downstream of RIP3. NSA inhibits necrosis by covalently modifying a protein called mixed lineage kinase domain-like protein (MLKL). Interestingly, NSA covalently modifies a cysteine present in human MLKL, but not in mouse MLKL, giving the compound species specificity. MLKL interacts directly with RIP3, and reducing the levels of MLKL protects cells against TNF-induced necrosis. Sun et al. also show that, upon necrosis induction, MLKL is strongly recruited to phosphorylated RIP3 and is subsequently phosphorylated by RIP3. Mutation of these phosphorylation sites on MLKL abrogates the ability of RIP3 and MLKL to signal for necrosis. These results establish MLKL as a functional substrate of RIP3 and suggest that MLKL functions as a key mediator of necrosis signaling.
Small-molecule inhibitors have significantly advanced our understanding of programmed necrosis. The RIP1 kinase inhibitor necrostatin-1 (Nec-1) (Degterev et al., 2008) and NSA inhibit distinct steps of programmed necrosis and provide critical insight into the hierarchical relationships among the factors controlling this process. Unlike Nec-1, NSA inhibits necrosis by covalently modifying MLKL. Because MLKL does not possess enzymatic function, it likely serves as an adaptor to bring the RIP1-RIP3 necrosome complex into proximity with other RIP3 substrates and downstream effectors (Figure 1) . In another study from the same laboratory, Wang et al. use NSA to identify the mitochondrial protein phosphatase, PGAM5, as one of these downstream effectors.
Genetic evidence in Drosophila suggests that PGAM5 regulates the function of the Parkinson's disease gene PINK1, suggesting a possible link between necrosis and neurodegeneration (Imai et al., 2010) . PGAM5 has two splice variants, PGAM5L and PGAM5S, and each one appears to have a distinct function in necrosis. In the presence of NSA, MLKL and PGAM5L binding to RIP3 is enhanced, and phosphorylation of PGAM5L by RIP3 is unaffected. Interestingly, the phosphorylation of PGAM5S is abolished in the presence of NSA, suggesting that the inhibitor likely stabilizes the RIP3 complex and prevents it from engaging the downstream effector PGAM5S. Thus, it appears that PGAM5L tethers the RIP1-RIP3-MLKL necrosome (complex II) to PGAM5S on the mitochondrial membrane (Figure 1) .
Mitochondrial fragmentation has been implicated in cell death. The association of the necrosome with PGAM5S appears to be a critical event for activation of Drp1, a GTPase that is essential for mitochondrial fission. PGAM5L dephosphorylates Drp-1 and activates its GTPase activity. Thus, RIP1-RIP3-MLKL-PGAM5L form a dynamic and transient complex that dissolves over time as the tertiary complex of PGAM5S-Drp-1 (complex III) becomes activated (Figure 1 ). RNAi-mediated silencing of MLKL, PGAM5, or Drp-1 or pharmacological inhibition of Drp-1 prevents mitochondrial fragmentation and necrosis. These results suggest a tantalizing mechanism in which the RIP1-RIP3 necrosome complex signals for necrosis by engaging the mitochondrial fission machinery.
Significantly, the ''mitochondria attack complex'' consisting of PGAM5 and Drp-1, but neither RIP1, RIP3, nor MLKL, is also required for necrosis induced by signals such as calcium flux and oxidative stress. Thus, these results provide strong evidence that extrinsic death receptormediated (e.g., TNF-like death cytokines) and intrinsic death receptor-independent signals (e.g., oxidative stress) converge upon the PGAM5-Drp-1 axis to induce necrosis.
These studies provide a significant advance in our understanding of programmed necrosis by identifying two downstream effectors of this process. More remains to be learned about MLKL and PGAM5, including the specificity of their roles in programmed necrosis and whether they are required for all necrosis that occurs in animals. Furthermore, the role of Drp-1 in necrosis needs to be further investigated to understand how mitochondrial fragmentation promotes this form of cell death. Necrotic cell death has long been neglected as a process lacking physiological relevance. Times have changed, and with broad physiological implications, a blueprint for programmed necrosis is now emerging. Much remains to be learned about how different forms of cell death are regulated, how they may influence each other, and whether we can augment necrosis as a therapeutic approach to compensate for mutations in cell death pathways. RIP1 is recruited to the activated TNFR-1 and undergoes heavy ubiquitination by E3 ligases such as TRAF2 and cIAP-1. This membrane-and receptor-associated complex, termed complex I, is responsible for NF-kB activation. As the membrane-associated complex I becomes internalized, deubiquitinases such as cylindromatosis (CYLD) removes the polyubiquitin chains on RIP1. The deubiquitination of RIP1 and inhibition of caspase 8 are crucial for the assembly of the secondary signaling complex (complex II). At this cytoplasmic complex, RIP1 likely phosphorylates RIP3 at S227, which in turn phosphorylates PGAM5L and MLKL at T357 and S358. These phosphorylation events are important for the RIP3 necrosis signaling complex to engage PGAM5S on the mitochondrial membrane, a step that is inhibited by the smallmolecule inhibitor NSA. Once activated by phosphorylation, the PGAM5L/PGAM5S complex dephosphorylates the mitochondrial fission regulator Drp1 to induce its dimerization and activation. Excessive Drp1 activity could lead to disruption of mitochondrial functions and other organelle and membrane damages that cumulate in programmed necrosis. The PGAM5L-PGAM5S-Drp1 mitochondrial attack complex (MAC) could also be activated by calcium flux or a surge of intracellular reactive oxygen species (ROS).
